Pyrrolidinedithiocarbamate ammonium
(Synonyms: 吡咯烷二硫代氨基甲酸铵; Ammonium pyrrolidinedithiocarbamate; PDTC ammonium; APDC) 目录号 : GC13575
A potent and reversible NF-κB inhibitor with antioxidant properties
Cas No.:5108-96-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
The human colon cancer cell line HT-29 is obtained and cells are grown in modified McCoy’s 5A medium supplemented with 10% fetal bovine serum. To study the effect of pyrrolidinedithiocarbamate ammonium on IL-8 production, HT-29 cells in 96-well plates are induced with 20 ng/mL of IL-1β for 18 h. Various concentrations (3-1000 μM) of pyrrolidinedithiocarbamate or its vehicle (culture medium) are added to the cells 30 min prior to IL-1β stimulation. The concentration of IL-8 in the supernatant is determined using solid-phase enzyme-linked immunosorbent assay[1]. |
|
Animal experiment: |
Animal Administration: [2]Pyrrolidinedithiocarbamate is administered intraperitoneally to mice at dose levels of 100 and 50 mg/kg. Mice are divided into a DSS-untreated group (normal group), DSS-treated control group, DSS+pyrrolidinedithiocarbamate-treated groupI (low-dose group), and DSS+pyrrolidinedithiocarbamate-treated groupII (high-dose group). In each group, the disease activity index score (DAI score), intestinal length, histological score, and the levels of activated NF-κB and inflammatory cytokines (IL-1β and TNF-α) in tissue are measured[2]. |
|
References: [1]. Németh ZH, et al. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. Immunol Lett. 2003 Jan 2;85(1):41-6. |
|
Pyrrolidinedithiocarbamate ammonium is a selective NF-κB inhibitor.
Pretreatment of cells with pyrrolidinedithiocarbamate (3-1000 μM) dose-dependently attenuate IL-8 production. Furthermore, pyrrolidinedithiocarbamate (100 μM) suppresses the accumulation of IL-8 mRNA. Pyrrolidinedithiocarbamate inhibits the activation of NF-κB, because pyrrolidinedithiocarbamate suppresses both NF-κB DNA binding and NF-κB-dependent transcriptional activity. NF-κB inhibition with pyrrolidinedithiocarbamate decrease IL-8 production by intestinal epithelial cells[1].
The DSS+pyrrolidinedithiocarbamate ammonium-treated groupII exhibits suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+pyrrolidinedithiocarbamate ammonium-treated groupII. These findings suggest that suppression of NF-κB activity by pyrrolidinedithiocarbamate ammonium can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. pyrrolidinedithiocarbamate ammonium is useful for the treatment of ulcerative colitis[2].
Reference:
[1]. Németh ZH, et al. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. Immunol Lett. 2003 Jan 2;85(1):41-6.
[2]. Qin JD, et al. Effect of ammonium pyrrolidine dithiocarbamate (PDTC) on NF-κB activation and CYP2E1 content of rats with immunological liver injury. Pharm Biol. 2014 Nov;52(11):1460-1466.
| Cas No. | 5108-96-3 | SDF | |
| 别名 | 吡咯烷二硫代氨基甲酸铵; Ammonium pyrrolidinedithiocarbamate; PDTC ammonium; APDC | ||
| 化学名 | ammonium pyrrolidine-1-carbodithioate | ||
| Canonical SMILES | [S-]C(N1CCCC1)=S.[NH4+] | ||
| 分子式 | C5H12N2S2 | 分子量 | 164.28 |
| 溶解度 | ≥50mg/mL in Water, ≥ 7.3mg/mL in DMSO, ≥ 12.975mg/mL in EtOH with gentle warming | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.0872 mL | 30.4358 mL | 60.8717 mL |
| 5 mM | 1.2174 mL | 6.0872 mL | 12.1743 mL |
| 10 mM | 0.6087 mL | 3.0436 mL | 6.0872 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。